Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co Announces Results For Phase 3 Trial Of Yervoy (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer


Thursday, 12 Sep 2013 04:25am EDT 

Bristol-Myers Squibb Company announced that it has reported results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel. The study's primary endpoint of overall survival (OS) did not reach statistical significance (HR = 0.85; 95% CI = 0.72-1.00; p = 0.053). However, anti-tumor activity was observed across some efficacy endpoints, including progression free-survival. These data will be presented at the 2013 European Cancer Congress in an oral session on September 28 (Abstract # 2850). 

Company Quote

1090.24
 --
28 Apr 2015